Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

SMILE for hyperopia: visual and refractive outcomes at 3 months

Search Title by author or title

Session Details

Session Title: SMILE, LASIK and Re-treatment

Session Date/Time: Monday 09/10/2017 | 14:30-16:00

Paper Time: 15:00

Venue: Room 2.1

First Author: : K.Pradhan NEPAL

Co Author(s): :    D. Reinstein   G. Carp   T. Archer   P. Dhungana   R. Khan        

Abstract Details

Purpose:

To evaluate visual and refractive outcomes of small incision lenticule extraction (SMILE) for hyperopia.

Setting:

Tilganga Institute of Ophthalmology, Kathmandu, Nepal

Methods:

Prospective study of vertex-centered hyperopic SMILE using the VisuMax femtosecond laser (Carl Zeiss Meditec). Inclusion criteria were intended sphere ≤+7.00 D, astigmatism ≤6.00 D, CDVA 20/40 or better, and age ≥21 years. Lenticule parameters were 6.3-6.7 mm diameter, 2 mm transition zone, 30 μm minimum thickness, and 120 μm cap thickness. Standard outcomes analysis was performed for the 3 month data, including contrast sensitivity using the Functional Vision Analyzer.

Results:

For 93 eyes treated, 3-month data was available for 76 (82%). Attempted SEQ was +5.64±1.17D (+1.00 to +6.50D), cylinder was 0.89±0.70D (0.00 to 3.50D). For eyes targeted for emmetropia (n=34), UDVA was 20/40 or better in 88% of eyes. SEQ relative to target was -0.13±0.86D (-2.20 to +3.00D), 59% within ±0.50 D. There was 1 line loss CDVA in 17% of eyes, one eye lost 2 lines (1.3%), and one eye lost 3 lines (1.3%), but recovered to 1 line lost at 9 months. No statistically significant change in contrast sensitivity.

Conclusions:

Refractive and visual outcomes 3 months after SMILE for hyperopia were promising, given the high degree of hyperopia corrected and relatively reduced CDVA in this population. The slight mean overcorrection would be expected to regress further by 1 year. Undercorrection of more than 1.00 D in 5 eyes might be partly explained by latent hyperopia in these young patients.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous